0 items

in your cart
$0.00

  • Search for Medications
  • Viewcart | Checkout
  • Manage Account
  •  
  • Click-to-Call  

Prescription Drug Search

Strengths available for Rimonabant :

Search for a drug:

 

Browse Alphabetically:

A · B · C · D · E · F · G · H · I · J · K · L · M · N
O · P · Q · R · S · T · U · V · W · X · Y · Z · #

Information about Canadian-Internet-Drugs.com

SSL Secured Website Certified Global Pharmacy Network Hacker Proof: Safe Shopping Experience 5th Anniversary 2002-2007

List of countries where we can ship Rimonabant:

  • Anguilla
  • Antigua and Barbuda
  • Austria
  • Bahamas
  • Bahrain
  • Belarus
  • Bulgaria
  • Colombia
  • Cook Islands
  • Cuba
  • Dominican Republic
  • Ecuador
  • El Salvador
  • Estonia
  • Finland
  • Gibraltar
  • Guadeloupe
  • Hungary
  • India
  • Indonesia
  • Iran
  • Japan
  • Korea, Republic of
  • Korea, South
  • Luxembourg
  • Malta
  • Netherlands
  • Netherlands Antilles
  • Peru
  • Portugal
  • Serbia
  • Slovakia
  • Slovenia
  • Sweden
  • Switzerland
  • Taiwan
  • Trinidad and Tobago
  • Tunisia
  • United Kingdom, UK
  • United States, US
View All Countries

Latest news releases on Rimonabant:

Rimonabant - Wikipedia

Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug that was first approved in Europe in 2006 but was withdrawn ...

Rimonabant | C22H21Cl3N4O - PubChem - The PubChem Project

Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1.

Rimonabant: From RIO to Ban - PubMed Central (PMC)

Endocannabinoid antagonism as a treatment for obesity and the metabolic syndrome became a hugely anticipated area of pharmacology at the start of the century. The CB1 ...

European Medicines Agency - - Acomplia

European Union agency responsible for the protection of public and animal health through the scientific evaluation and supervision of medicines.

Rimonabant - an overview | ScienceDirect Topics

Atrial fibrillation has been attributed to rimonabant in two cases [114 A]. • A man who took rimonabant for 5 weeks developed palpitation, fatigue, and exertional ...

Acomplia: Uses, Dosage, Side Effects & Warnings - Drugs.com

Sanofi-Aventis has withdrawn rimonabant from the market globally and it is no longer under development. 1 Acomplia was officially withdrawn by the European Medicines ...

Single and multiple doses of rimonabant antagonize acute ...

Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users

Acomplia (Rimonabant) – Investigational Agent for the ...

Developed by Sanofi-Aventis, Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity. It works...Read More...

Journal of Obesity - Rimonabant: From RIO to Ban

Endocannabinoid antagonism as a treatment for obesity and the metabolic syndrome became a hugely anticipated area of pharmacology at the start of the century. The CB1 ...

Rimonabant hydrochloride ≥98% (HPLC) | Sigma-Aldrich

Packaging 5, 25 mg in glass bottle Biochem/physiol Actions Rimonabant hydrochloride (SR-141716A) is a potent and selective CB1 cannabinoid ...

Customer Service
1-866-799-3435 - Use ref# 1164 | Contact Form
Copyright © 2018 Canadian-Internet-Drugs.com All rights reserved. Disclaimer | Privacy Policy
Accepted Credit Cards and Payment: VISA, MASTERCARD and eCHECK